Home » News
Celprogen introduces STEMC7007 a Human Pancreatic Stem Cell Proliferator that increases Pancreatic Beta and Alpha Cell populations

Celprogen introduces STEMC7007 a Human Pancreatic Stem Cell Proliferator that increases Pancreatic Beta and Alpha Cell populations

 

 

 

 

 

 

 

 

TORRANCE, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced, that they have developed STEMC7007 a synthetic molecule that is capable of stimulating growth and proliferation of pancreatic Beta and Alpha cell populations. This molecule can be administrated by the following methods: intravenous, intra-peritoneal and intramuscular injections, and oral doses. The molecule STEMC7007 activates adult pancreatic Beta and Alpha cell populations. The STEMC7007 molecule establishes normal Beta cell function in diabetic cell populations by producing and secreting insulin and glucagon in in-vitro cell culture system.
The present invention relates to increasing the insulin and Glucagon levels in diabetic in-vivo models. The molecule STEMC7007, has been developed and optimized by Celprogen utilizing proprietary stem cell tissue culture technology. This technology will have a greater impact for diabetic patients; it works by restoring the human beta and alpha cell populations in the pancreas. The Alpha cells of the pancreas are involved in glucagon production whereas the Beta cells are involved in Insulin production. STEMC7007 works at the protein and gene expression levels to increase:
1. Insulin gene expression levels as well as this hormone secretion by the pancreas.
2. Glucagon gene expression levels as well as this hormone secretion by the pancreas.
3. Somatostatin gene expression as well as this hormone secretion by the pancreas.
4. Glucose transporter gene expression and increase protein levels
“STEMC7007-Pancreatic Stem Cell Proliferator - is the regenerative molecule for the human pancreas- it work on the entire repertoire of pancreatic function “Jay Sharma. This molecule STEMC7007 is an interesting factor to be added to regenerative medicine therapy for the pancreas and also for diabetic patient therapy.
About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in Torrance, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.
 
For additional information on the product line contact:
Jay Sharma
Phone: 310 542 8822
info@celprogen.com
www.celprogen.com
Back to News Listing